Jönsson, BengtBengtJönssonHorisberger, BrunoBrunoHorisbergerBruguera, MiguelMiguelBrugueraMatter, LukasLukasMatter2024-10-252024-10-251991https://boris-portal.unibe.ch/handle/20.500.12422/160922The availability and efficacy of recombinant deoxyribonucleic acid yeast-derived hepatitis-B vaccine, at a price much lower than the previously available plasma-derived hepatitis-B vaccines against hepatitis-B virus infections, motivate a new cost-benefit analysis of hepatitis-B vaccination. Spanish data were used to calculate direct and indirect costs of hepatitis-B infection and the costs and benefits of different vaccination strategies in defined risk groups of the Spanish population. A vaccination program will reduce direct expenditures for hepatitis B if the attack rate in the target population is higher than 4.9%. If indirect costs are included, the threshold for cost saving is reduced to 0.9%. The results are sensitive to the price of the vaccine, the duration of protection, assumptions about consequences for quality of life, and to indirect costs.enarticle10.7892/boris.11513110.1017/S0266462300005754